Sibylla Corporate - Video

At Sibylla, we believe in a social engagement that science should never fail. During the covid-19 pandemic, we refocused our activity on a not-for-profit basis to release results immediately, having them promptly available for the scientific community. We found a compound active against malaria that was able to reduce the coronavirus infection in cells. A dose study is needed at preclinical and clinical levels to repurpose that drug. Although Sibylla cannot embark on such a study today, our results could be used by the pharmaceutical industry in case of necessity.